These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 18445010)

  • 1. Acquired von Willebrand syndrome.
    Alvarez MT; Jimenez-Yuste V; Gracia J; Quintana M; Hernandez-Navarro F
    Haemophilia; 2008 Jul; 14(4):856-8. PubMed ID: 18445010
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on the management of von Willebrand disease.
    Federici AB
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):29-30. PubMed ID: 18322438
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant von Willebrand factor.
    Schwarz HP; Turecek PL; Pichler L; Mitterer A; Mundt W; Dorner F; Roussi J; Drouet L
    Thromb Haemost; 1997 Jul; 78(1):571-6. PubMed ID: 9198218
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of single factor deficiencies: a case study approach.
    Marques MB
    Clin Lab Sci; 2003; 16(2):120-2. PubMed ID: 12757193
    [No Abstract]   [Full Text] [Related]  

  • 7. Preventing excessive bleeding in patients with von Willebrand disease.
    Gill JC
    Clin Adv Hematol Oncol; 2006 Mar; 4(3):207-9. PubMed ID: 16728929
    [No Abstract]   [Full Text] [Related]  

  • 8. von Willebrand disease in the 21st century: current approaches and new challenges.
    Mannucci PM; Federici AB; James AH; Kessler CM
    Haemophilia; 2009 Sep; 15(5):1154-8. PubMed ID: 19624761
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plasma-derived von Willebrand factor/factor VIII concentrate (Wilate).
    Med Lett Drugs Ther; 2010 Jun; 52(1340):46-7. PubMed ID: 20539265
    [No Abstract]   [Full Text] [Related]  

  • 12. [Willebrand disease].
    Lequièvre V
    Rev Infirm; 2006; (122):22-4. PubMed ID: 16881452
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of acquired von Willebrand disease with lenalidomide leading to dramatic resolution of intractable gastrointestinal bleeding: A case report.
    Thomas W; Warner E; Cameron E; Symington E
    Haemophilia; 2018 May; 24(3):e140-e142. PubMed ID: 29578269
    [No Abstract]   [Full Text] [Related]  

  • 14. New treatment for von Willebrand disease.
    Belavic JM
    Nurse Pract; 2010 Sep; 35(9):13-4. PubMed ID: 20720463
    [No Abstract]   [Full Text] [Related]  

  • 15. [Inborn and acquired von Willebrand disease].
    Schneppenheim R; Budde U
    Hamostaseologie; 2008 Dec; 28(5):312-9. PubMed ID: 19132162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal and fetal outcomes in pregnancies affected by von Willebrand disease type 2.
    Burlingame J; McGaraghan A; Kilpatrick S; Hambleton J; Main E; Laros RK
    Am J Obstet Gynecol; 2001 Jan; 184(2):229-30. PubMed ID: 11174508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of von Willebrand disease subtypes: implications for treatment.
    Budde U
    Haemophilia; 2008 Nov; 14 Suppl 5():27-38. PubMed ID: 18786008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profile of Optivate® (high-purity factor VIII/von Willebrand factor concentrate) in treating von Willebrand disease.
    Shaikh-Zaidi R; Lubetsky A; Inbal A; Dash C
    Haemophilia; 2016 Jan; 22(1):e64-7. PubMed ID: 26572507
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?
    Drillaud N; Ardillon L; Ternisien C; Valentin JB; Fouassier M; Gillet B; Gruel Y; Sigaud M; Horvais V; Bene MC; Trossaërt M
    Transfus Med Rev; 2020 Apr; 34(2):128-129. PubMed ID: 31813707
    [No Abstract]   [Full Text] [Related]  

  • 20. [Acquired von Willebranol syndrome--its pathophysiology, diagnosis and treatment].
    Mohri H
    Rinsho Ketsueki; 2001 Jul; 42(7):525-36. PubMed ID: 11524842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.